A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of HUMIRA (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Phase of Trial: Phase IV
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs Adalimumab (Primary) ; Azathioprine; Mercaptopurine
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors AbbVie
- 09 May 2018 Planned End Date changed from 26 Apr 2027 to 6 Apr 2027.
- 09 May 2018 Planned primary completion date changed from 26 Apr 2027 to 6 Apr 2027.
- 09 Sep 2013 Actual initiation date changed from Apr 2013 to May 2013 as reported by ClinicalTrials.gov.